Document is current
Any future updates will be listed below
-
Authors
Song, Feifei https://orcid.org/0000-0002-8866-1270
Tsahouridis, Ourania https://orcid.org/0000-0003-0621-6753
Stucchi, Simone
Walhart, Tara
Mendell, Sophie
Hardy, P. Brian
Axtman, Matthew
Guduru, Shiva K. R.
Gilbert, Thomas S. K.
Graves, Lee M.
Herring, Laura E. https://orcid.org/0000-0003-4496-7312
Savoldo, Barbara
Ma, Xingcong
Woodcock, Mark https://orcid.org/0000-0001-7348-4980
Milner, Justin J. https://orcid.org/0000-0002-0752-2130
Ivanova, Anastasia
Pearce, Kenneth H. https://orcid.org/0000-0001-8138-5421
Xu, Yang https://orcid.org/0000-0003-1468-2703
Dotti, Gianpietro https://orcid.org/0000-0002-2639-8526
-
Funding
Funding for this research was provided by:
National Cancer Center (R01CA256898)
National Cancer Center (R01CA247436)
National Cancer Center (R01CA243543)
National Cancer Center (R01CA193140)
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 25 November 2024
First Online: 8 January 2025
Competing interests
: G.D. serves in the SAB of NanoCells, Estella, Arovella and Outspace Bio and is cofounder of Persistence Bio. A patent application has been submitted for the use of the identified KIs. Y.X. consults for Lumosa Therapeutics. The remaining authors declared no potential competing interests.
